CN102697785B - 治疗或防治激素变异症状的方法 - Google Patents
治疗或防治激素变异症状的方法 Download PDFInfo
- Publication number
- CN102697785B CN102697785B CN201210178935.XA CN201210178935A CN102697785B CN 102697785 B CN102697785 B CN 102697785B CN 201210178935 A CN201210178935 A CN 201210178935A CN 102697785 B CN102697785 B CN 102697785B
- Authority
- CN
- China
- Prior art keywords
- hot flashes
- risperidone
- symptoms
- receptors
- dopamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000024891 symptom Diseases 0.000 title claims abstract description 58
- 229940088597 hormone Drugs 0.000 title claims abstract description 18
- 239000005556 hormone Substances 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title abstract description 15
- 206010060800 Hot flush Diseases 0.000 claims description 81
- 208000033830 Hot Flashes Diseases 0.000 claims description 75
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 49
- 229960001534 risperidone Drugs 0.000 claims description 48
- 238000011282 treatment Methods 0.000 claims description 26
- 230000003054 hormonal effect Effects 0.000 claims description 23
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 230000036565 night sweats Effects 0.000 claims description 11
- 206010029410 night sweats Diseases 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 8
- 206010033557 Palpitations Diseases 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 90
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 37
- 229960003638 dopamine Drugs 0.000 abstract description 20
- 229940044551 receptor antagonist Drugs 0.000 abstract description 8
- 239000002464 receptor antagonist Substances 0.000 abstract description 8
- 102000005962 receptors Human genes 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- 102000015554 Dopamine receptor Human genes 0.000 description 20
- 108050004812 Dopamine receptor Proteins 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 12
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 12
- 229940076279 serotonin Drugs 0.000 description 12
- 102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 11
- 101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 11
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 229960004372 aripiprazole Drugs 0.000 description 9
- 229960004170 clozapine Drugs 0.000 description 9
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 9
- 229960000607 ziprasidone Drugs 0.000 description 9
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 229960005017 olanzapine Drugs 0.000 description 8
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 8
- 230000001331 thermoregulatory effect Effects 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- 230000008485 antagonism Effects 0.000 description 7
- 230000000561 anti-psychotic effect Effects 0.000 description 7
- 230000009245 menopause Effects 0.000 description 7
- 229960002748 norepinephrine Drugs 0.000 description 7
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
- 229960004431 quetiapine Drugs 0.000 description 7
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 102000000543 Histamine Receptors Human genes 0.000 description 6
- 108010002059 Histamine Receptors Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 6
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 6
- 229960002896 clonidine Drugs 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 238000002657 hormone replacement therapy Methods 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 102000009151 Luteinizing Hormone Human genes 0.000 description 5
- 108010073521 Luteinizing Hormone Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 239000003693 atypical antipsychotic agent Substances 0.000 description 5
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 5
- 230000003291 dopaminomimetic effect Effects 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 210000003016 hypothalamus Anatomy 0.000 description 5
- 229940040129 luteinizing hormone Drugs 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- 230000007958 sleep Effects 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010040108 Serotonin syndrome Diseases 0.000 description 4
- 210000001971 anterior hypothalamus Anatomy 0.000 description 4
- 229940127088 antihypertensive drug Drugs 0.000 description 4
- 150000003943 catecholamines Chemical class 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000004031 partial agonist Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 4
- 229960004496 zotepine Drugs 0.000 description 4
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- 206010020843 Hyperthermia Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 229940005529 antipsychotics Drugs 0.000 description 3
- 229940127236 atypical antipsychotics Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 230000001713 cholinergic effect Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000036031 hyperthermia Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 229960001603 tamoxifen Drugs 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 2
- 206010027304 Menopausal symptoms Diseases 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 210000001943 adrenal medulla Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 230000001090 anti-dopaminergic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 230000036757 core body temperature Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 210000003814 preoptic area Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 239000002400 serotonin 2A antagonist Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- 101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- CGQCWMIAEPEHNQ-UHFFFAOYSA-N Vanillylmandelic acid Chemical compound COC1=CC(C(O)C(O)=O)=CC=C1O CGQCWMIAEPEHNQ-UHFFFAOYSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 229940056213 abilify Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940035811 conjugated estrogen Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- NMCHYWGKBADVMK-UHFFFAOYSA-N fenetylline Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCNC(C)CC1=CC=CC=C1 NMCHYWGKBADVMK-UHFFFAOYSA-N 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940103136 risperidone 2 mg Drugs 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000028016 temperature homeostasis Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 238000011539 total abdominal hysterectomy Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960001968 veralipride Drugs 0.000 description 1
- RYJXBGGBZJGVQF-UHFFFAOYSA-N veralipride Chemical compound COC1=CC(S(N)(=O)=O)=CC(C(=O)NCC2N(CCC2)CC=C)=C1OC RYJXBGGBZJGVQF-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/638,282 US7645750B2 (en) | 2006-12-13 | 2006-12-13 | Method of treating symptoms of hormonal variations |
| US11/638,282 | 2006-12-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800463514A Division CN101588804B (zh) | 2006-12-13 | 2007-11-27 | 治疗或防治激素变异症状的方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102697785A CN102697785A (zh) | 2012-10-03 |
| CN102697785B true CN102697785B (zh) | 2015-02-18 |
Family
ID=39528142
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210178935.XA Expired - Fee Related CN102697785B (zh) | 2006-12-13 | 2007-11-27 | 治疗或防治激素变异症状的方法 |
| CN2007800463514A Expired - Fee Related CN101588804B (zh) | 2006-12-13 | 2007-11-27 | 治疗或防治激素变异症状的方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800463514A Expired - Fee Related CN101588804B (zh) | 2006-12-13 | 2007-11-27 | 治疗或防治激素变异症状的方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7645750B2 (OSRAM) |
| EP (1) | EP2101781B1 (OSRAM) |
| JP (1) | JP4643742B2 (OSRAM) |
| KR (1) | KR101435695B1 (OSRAM) |
| CN (2) | CN102697785B (OSRAM) |
| AT (1) | ATE506065T1 (OSRAM) |
| CA (1) | CA2671954C (OSRAM) |
| DE (1) | DE602007014102D1 (OSRAM) |
| MY (1) | MY162095A (OSRAM) |
| TW (1) | TWI330083B (OSRAM) |
| WO (1) | WO2008087491A2 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ527142A (en) | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
| US8631151B2 (en) | 2006-05-18 | 2014-01-14 | Intel Corporation | Techniques for guaranteeing bandwidth with aggregate traffic |
| US7645750B2 (en) * | 2006-12-13 | 2010-01-12 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Method of treating symptoms of hormonal variations |
| CA2673481A1 (en) * | 2006-12-19 | 2008-06-26 | University Of Virginia Patent Foundation | Combined effects of topiramate and ondansetron on alcohol consumption |
| WO2009029308A1 (en) * | 2007-08-27 | 2009-03-05 | University Of Virginia Patent Foundation | Medication combinations for the treatment of alcoholism and drug addiction |
| US8420624B2 (en) * | 2007-12-04 | 2013-04-16 | Yung Shin Pharm. Ind. Co., Ltd. | Methods for treating or preventing symptoms of hormonal variations |
| NZ588037A (en) | 2008-02-28 | 2012-08-31 | Univ Virginia Patent Found | Serotonin transporter gene SLC6A4 and treatment of alcoholism |
| US8461102B2 (en) | 2010-03-02 | 2013-06-11 | George E. Royster, JR. | Methods and compositions for treating and preventing symptoms of hormonal variations |
| AU2011223807B2 (en) * | 2010-03-02 | 2016-05-12 | Fervent Pharmaceuticals, Llc | Methods and compositions for treating or preventing symptoms of hormonal variations |
| AU2011280039B2 (en) * | 2010-06-30 | 2014-08-07 | Victoria Link Ltd | Methods and compositions for treatment of multiple sclerosis |
| CA2804174A1 (en) * | 2010-07-02 | 2012-01-05 | University Of Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| WO2012154174A1 (en) * | 2011-05-10 | 2012-11-15 | Liu Chui Yu | Methods for treating insomnia |
| CA2848211A1 (en) | 2011-09-09 | 2013-03-14 | University Of Virginia Patent Foundation | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence |
| KR20160055135A (ko) * | 2013-07-22 | 2016-05-17 | 오하이오 스테이트 이노베이션 파운데이션 | 일과성 열감의 발생을 감소시키는 방법 |
| US11147856B2 (en) * | 2015-04-07 | 2021-10-19 | Meiji Co., Ltd. | Hot flash-suppressing agent |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4096254A (en) * | 1976-05-10 | 1978-06-20 | Richardson-Merrell Inc. | Method of treating the symptoms of menopause and osteoporosis |
| FR2358892A1 (fr) * | 1976-07-19 | 1978-02-17 | Ile De France | N(1'-allyl 2'-pyrrolidylmethyl)2,3-dimethoxy 5-sulfamoyl benzamide, ses derives |
| US5654011A (en) * | 1996-07-30 | 1997-08-05 | Energetics, Inc. | Dietary supplements |
| AU9621598A (en) * | 1997-10-20 | 1999-05-10 | Novo Nordisk A/S | Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive |
| FR2779579B1 (fr) * | 1998-06-09 | 2000-08-25 | Thomson Csf | Dispositif de commande optique pour l'emission et la reception d'un radar large bande |
| US6310098B1 (en) * | 1999-07-22 | 2001-10-30 | University Of Rochester | Method of treating symptoms of hormonal variation, including hot flashes |
| US6613792B1 (en) * | 1999-08-02 | 2003-09-02 | Designed Nutritional Products, Inc. | Treatment of premenstrual syndrome and menopause |
| JP2003506483A (ja) * | 1999-08-13 | 2003-02-18 | ベラ・ファーマシューティカルズ・インコーポレイテッド | シクロベンザプリンおよびその組成物による全般性不安障害の処置 |
| US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| EP1373203A1 (en) * | 2001-03-29 | 2004-01-02 | Bristol-Myers Squibb Company | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| WO2003037334A1 (en) * | 2001-10-31 | 2003-05-08 | Merck & Co., Inc. | Method for treating or preventing symptoms of hormonal variation including hot flashes |
| CN1465348A (zh) | 2002-07-05 | 2004-01-07 | 冯威健 | 复方消融合剂及其在用作制备治疗肿瘤药物上的应用 |
| US20040127489A1 (en) * | 2002-07-29 | 2004-07-01 | David Pickar | Novel antipsychotic combination therapies and compositions useful therein |
| RU2340333C2 (ru) * | 2002-08-15 | 2008-12-10 | Вайет | Агонизм 5нт2a -рецептора для лечения нарушения функции терморегуляции |
| JP2006514633A (ja) * | 2002-11-26 | 2006-05-11 | アレックザ ファーマシューティカルズ， インコーポレイテッド | 吸入によって送達される抗精神病薬を用いた頭痛の治療 |
| US7855195B2 (en) * | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| JP2007537232A (ja) * | 2004-05-11 | 2007-12-20 | ファイザー・プロダクツ・インク | 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ |
| WO2005120523A1 (en) * | 2004-06-04 | 2005-12-22 | Mood Management Sciences, Llc | Methods and compositions for treating mood disorder |
| TW200631584A (en) | 2004-11-15 | 2006-09-16 | Akzo Nobel Nv | A medicament related to mirtazapine for the treatment of hot flush |
| US20060122127A1 (en) * | 2004-11-17 | 2006-06-08 | Cypress Bioscience, Inc. | Methods for reducing the side effects associated with mirtzapine treatment |
| US7645750B2 (en) * | 2006-12-13 | 2010-01-12 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Method of treating symptoms of hormonal variations |
-
2006
- 2006-12-13 US US11/638,282 patent/US7645750B2/en active Active
-
2007
- 2007-10-26 TW TW096140356A patent/TWI330083B/zh not_active IP Right Cessation
- 2007-11-27 DE DE602007014102T patent/DE602007014102D1/de active Active
- 2007-11-27 EP EP07872103A patent/EP2101781B1/en not_active Not-in-force
- 2007-11-27 JP JP2009540891A patent/JP4643742B2/ja not_active Expired - Fee Related
- 2007-11-27 CA CA2671954A patent/CA2671954C/en active Active
- 2007-11-27 CN CN201210178935.XA patent/CN102697785B/zh not_active Expired - Fee Related
- 2007-11-27 KR KR1020097012120A patent/KR101435695B1/ko not_active Expired - Fee Related
- 2007-11-27 MY MYPI20092347A patent/MY162095A/en unknown
- 2007-11-27 AT AT07872103T patent/ATE506065T1/de not_active IP Right Cessation
- 2007-11-27 WO PCT/IB2007/004514 patent/WO2008087491A2/en not_active Ceased
- 2007-11-27 CN CN2007800463514A patent/CN101588804B/zh not_active Expired - Fee Related
-
2009
- 2009-12-11 US US12/636,552 patent/US20100093762A1/en not_active Abandoned
-
2015
- 2015-03-03 US US14/637,200 patent/US20150246056A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI330083B (en) | 2010-09-11 |
| WO2008087491A2 (en) | 2008-07-24 |
| DE602007014102D1 (de) | 2011-06-01 |
| EP2101781A4 (en) | 2010-02-10 |
| CA2671954A1 (en) | 2008-07-24 |
| CN102697785A (zh) | 2012-10-03 |
| CA2671954C (en) | 2012-01-03 |
| US20150246056A1 (en) | 2015-09-03 |
| KR101435695B1 (ko) | 2014-09-02 |
| KR20090103876A (ko) | 2009-10-01 |
| CN101588804A (zh) | 2009-11-25 |
| JP4643742B2 (ja) | 2011-03-02 |
| EP2101781B1 (en) | 2011-04-20 |
| EP2101781A2 (en) | 2009-09-23 |
| US20100093762A1 (en) | 2010-04-15 |
| US20080146541A1 (en) | 2008-06-19 |
| WO2008087491A8 (en) | 2008-10-30 |
| CN101588804B (zh) | 2012-09-05 |
| TW200825082A (en) | 2008-06-16 |
| JP2010522137A (ja) | 2010-07-01 |
| MY162095A (en) | 2017-05-31 |
| US7645750B2 (en) | 2010-01-12 |
| WO2008087491A3 (en) | 2008-12-18 |
| ATE506065T1 (de) | 2011-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102697785B (zh) | 治疗或防治激素变异症状的方法 | |
| US8420624B2 (en) | Methods for treating or preventing symptoms of hormonal variations | |
| US9700548B2 (en) | Antihistamines combined with dietary supplements for improved health | |
| JPH06508836A (ja) | 光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物 | |
| AU2016213776B2 (en) | Methods and compositions for treating or preventing symptoms of hormonal variations | |
| MXPA05003980A (es) | Metodo para tratar sintomas vasomotores, que comprende un compuesto que tiene actividad inhibidora de retoma de norepinefrina y actividad antagonistica 5-ht2a. | |
| WO2015089489A1 (en) | Antihistamines in combination with a range of substance for improved health | |
| US10806722B1 (en) | Method and compound for treatment of menopausal symptoms | |
| JPH06509073A (ja) | 光学的に純粋なｓ（−）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物 | |
| CA2866494C (en) | Compounds, compositions, and uses thereof for treatment of menopausal symptoms and menopausal hot flashes | |
| CN101189043A (zh) | 肾上腺素能α2B拮抗剂用于治疗血管舒缩症状的应用 | |
| CN1705475A (zh) | 通过具有去甲肾上腺素重摄取抑制剂活性和5－ht2a拮抗活性的化合物治疗血管舒缩症的方法 | |
| JP2007515395A (ja) | 血管運動症状の治療方法 | |
| JP2008255058A (ja) | 睡眠障害予防治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150218 |